152 related articles for article (PubMed ID: 12603176)
1. Investigation of the mutual pharmacokinetic interactions between bosentan, a dual endothelin receptor antagonist, and simvastatin.
Dingemanse J; Schaarschmidt D; van Giersbergen PL
Clin Pharmacokinet; 2003; 42(3):293-301. PubMed ID: 12603176
[TBL] [Abstract][Full Text] [Related]
2. Clinical pharmacology of bosentan, a dual endothelin receptor antagonist.
Dingemanse J; van Giersbergen PL
Clin Pharmacokinet; 2004; 43(15):1089-115. PubMed ID: 15568889
[TBL] [Abstract][Full Text] [Related]
3. In vivo and in vitro studies exploring the pharmacokinetic interaction between bosentan, a dual endothelin receptor antagonist, and glyburide.
van Giersbergen PL; Treiber A; Clozel M; Bodin F; Dingemanse J
Clin Pharmacol Ther; 2002 Apr; 71(4):253-62. PubMed ID: 11956508
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic interactions of almorexant with midazolam and simvastatin, two CYP3A4 model substrates, in healthy male subjects.
Hoch M; Hoever P; Alessi F; Theodor R; Dingemanse J
Eur J Clin Pharmacol; 2013 Mar; 69(3):523-32. PubMed ID: 22990330
[TBL] [Abstract][Full Text] [Related]
5. Single- and multiple-dose pharmacokinetics of bosentan and its interaction with ketoconazole.
van Giersbergen PL; Halabi A; Dingemanse J
Br J Clin Pharmacol; 2002 Jun; 53(6):589-95. PubMed ID: 12047483
[TBL] [Abstract][Full Text] [Related]
6. Inhibitory and inductive effects of rifampin on the pharmacokinetics of bosentan in healthy subjects.
van Giersbergen PL; Treiber A; Schneiter R; Dietrich H; Dingemanse J
Clin Pharmacol Ther; 2007 Mar; 81(3):414-9. PubMed ID: 17251982
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic interaction between tadalafil and bosentan in healthy male subjects.
Wrishko RE; Dingemanse J; Yu A; Darstein C; Phillips DL; Mitchell MI
J Clin Pharmacol; 2008 May; 48(5):610-8. PubMed ID: 18305126
[TBL] [Abstract][Full Text] [Related]
8. Mutual pharmacokinetic interactions between bosentan and lopinavir/ritonavir in healthy participants.
Dingemanse J; van Giersbergen PL; Patat A; Nilsson PN
Antivir Ther; 2010; 15(2):157-63. PubMed ID: 20386070
[TBL] [Abstract][Full Text] [Related]
9. Lack of a pharmacokinetic interaction between oral treprostinil and bosentan in healthy adult volunteers.
Gotzkowsky SK; Dingemanse J; Lai A; Mottola D; Laliberte K
J Clin Pharmacol; 2010 Jul; 50(7):829-34. PubMed ID: 20133511
[TBL] [Abstract][Full Text] [Related]
10. Influence of severe renal dysfunction on the pharmacokinetics and metabolism of bosentan, a dual endothelin receptor antagonist.
Dingemanse J; van Giersbergen PL
Int J Clin Pharmacol Ther; 2002 Jul; 40(7):310-6. PubMed ID: 12139208
[TBL] [Abstract][Full Text] [Related]
11. Mutual pharmacokinetic interactions between steady-state bosentan and sildenafil.
Burgess G; Hoogkamer H; Collings L; Dingemanse J
Eur J Clin Pharmacol; 2008 Jan; 64(1):43-50. PubMed ID: 18040672
[TBL] [Abstract][Full Text] [Related]
12. Influence of age and cytochrome P450 2C9 genotype on the steady-state disposition of diclofenac and celecoxib.
Brenner SS; Herrlinger C; Dilger K; Mürdter TE; Hofmann U; Marx C; Klotz U
Clin Pharmacokinet; 2003; 42(3):283-92. PubMed ID: 12603175
[TBL] [Abstract][Full Text] [Related]
13. Lack of pharmacokinetic interaction of mipomersen sodium (ISIS 301012), a 2'-O-methoxyethyl modified antisense oligonucleotide targeting apolipoprotein B-100 messenger RNA, with simvastatin and ezetimibe.
Yu RZ; Geary RS; Flaim JD; Riley GC; Tribble DL; vanVliet AA; Wedel MK
Clin Pharmacokinet; 2009; 48(1):39-50. PubMed ID: 19071883
[TBL] [Abstract][Full Text] [Related]
14. Influence of food intake and formulation on the pharmacokinetics and metabolism of bosentan, a dual endothelin receptor antagonist.
Dingemanse J; Bodin F; Weidekamm E; Kutz K; van Giersbergen P
J Clin Pharmacol; 2002 Mar; 42(3):283-9. PubMed ID: 11865964
[TBL] [Abstract][Full Text] [Related]
15. Clarithromycin substantially increases steady-state bosentan exposure in healthy volunteers.
Markert C; Schweizer Y; Hellwig R; Wirsching T; Riedel KD; Burhenne J; Weiss J; Mikus G; Haefeli WE
Br J Clin Pharmacol; 2014 Jan; 77(1):141-8. PubMed ID: 23738582
[TBL] [Abstract][Full Text] [Related]
16. Multiple-dose pharmacokinetics, safety, and tolerability of bosentan, an endothelin receptor antagonist, in healthy male volunteers.
Weber C; Schmitt R; Birnboeck H; Hopfgartner G; Eggers H; Meyer J; van Marle S; Viischer HW; Jonkman JH
J Clin Pharmacol; 1999 Jul; 39(7):703-14. PubMed ID: 10392325
[TBL] [Abstract][Full Text] [Related]
17. Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil.
Treiber A; Schneiter R; Häusler S; Stieger B
Drug Metab Dispos; 2007 Aug; 35(8):1400-7. PubMed ID: 17496208
[TBL] [Abstract][Full Text] [Related]
18. Duration of effect of grapefruit juice on the pharmacokinetics of the CYP3A4 substrate simvastatin.
Lilja JJ; Kivistö KT; Neuvonen PJ
Clin Pharmacol Ther; 2000 Oct; 68(4):384-90. PubMed ID: 11061578
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of potential inductive effects of aprepitant on cytochrome P450 3A4 and 2C9 activity.
Shadle CR; Lee Y; Majumdar AK; Petty KJ; Gargano C; Bradstreet TE; Evans JK; Blum RA
J Clin Pharmacol; 2004 Mar; 44(3):215-23. PubMed ID: 14973304
[TBL] [Abstract][Full Text] [Related]
20. Warfarin and bosentan interaction in a patient with pulmonary hypertension secondary to bilateral pulmonary emboli.
Spangler ML; Saxena S
Clin Ther; 2010 Jan; 32(1):53-6. PubMed ID: 20171411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
